Lumentum stock price extends rally after Aletheia lifts target to $500 ahead of Feb. 3 earnings
22 January 2026
1 min read

Lumentum stock price extends rally after Aletheia lifts target to $500 ahead of Feb. 3 earnings

New York, January 21, 2026, 19:08 ET — After-hours

  • Shares jumped about 1.6% on Wednesday, following a nearly 10% rally the previous day
  • Aletheia Capital raised its price target to $500, citing strong demand for high-speed optical lasers
  • Investors are waiting on Lumentum’s fiscal Q2 report, due Feb. 3, for updates on orders, pricing, and supply

Lumentum Holdings Inc (LITE.O) shares rose about 1.6% Wednesday, last seen trading near $362.44 in after-hours. During the day, the stock fluctuated from $350.26 up to $376.06, with roughly 5 million shares changing hands.

The optical components maker jumped once more, catching eyes in a market hungry for data-center winners. Lumentum rose 10.05% Tuesday, defying the overall market slump. 1

Skye Chen at Aletheia Capital raised Lumentum’s price target sharply, from $330 to $500, on Tuesday, sticking with a buy rating. The analyst pointed to robust demand for EMLs—electro-absorption modulated lasers used in high-speed optical links—as the key driver. Chen also noted stronger pricing power and a quicker shift to next-gen laser technology. 2

This matter is key for investors hunting the top performers amid major cloud providers upgrading to faster data center connections. Investors.com highlighted the focus on suppliers powering the move from copper to optical links, fueled by the rapid growth of AI server clusters. 3

The broader market lifted spirits Wednesday, with the S&P 500 climbing 1.16%. IPG Photonics, the laser specialist, surged 8.49%, while nLIGHT nudged up 1.52%, according to MarketWatch data. 4

Lumentum’s recent surge has thrust the stock’s daily volatility into the spotlight again. Traders have leaned on the name for fast plays tied to the AI infrastructure boom, a strategy that can quickly unravel if sentiment turns against it.

A regulatory filing showed Chief Accounting Officer Matthew Joseph Sepe had 563 shares withheld at $343.27 each on Jan. 15 to cover income taxes tied to restricted stock units vesting. Following this, he still held 41,514 shares. 5

Lumentum plans to release its fiscal second-quarter earnings after the market closes on Feb. 3. The company will then host an audio webcast at 5:00 p.m. ET. 6

Risks remain. A stumble in demand, pricing, or supply of the high-speed components investors are wagering on could hit the stock hard, especially after two straight days of strong gains.

On Feb. 3, the rally meets its next test when Lumentum reports earnings and provides guidance for the coming quarter.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Exxon Mobil stock price jumps to a fresh 52-week high after hours — here’s what investors watch next
Previous Story

Exxon Mobil stock price jumps to a fresh 52-week high after hours — here’s what investors watch next

MercadoLibre stock ticks up after-hours as fresh SEC filing shows $238 mln fund stake — what to watch next (MELI)
Next Story

MercadoLibre stock ticks up after-hours as fresh SEC filing shows $238 mln fund stake — what to watch next (MELI)

Go toTop